Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structures

Kraitzer, Amir; Ofek, Lia; Schreiber, Reut; Zilberman, Meital

doi:10.1016/j.jconrel.2007.11.011

Cited by 29 publications

(31 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 In a study by Kraitzer et al core-shell fibers composed of a polyglyconate core and a porous PDLGA shell loaded with the anti-proliferative agent paclitaxel were fabricated through emulsion electrospinning. 140 They showed that copolymer composition had an effect on release profile. A 50/50 formulation released 70% of the drug, whereas a 75/25 formulation released only 13% after 20 week release study.…”

Section: Fiber Diameter and Porositymentioning

confidence: 99%

See 1 more Smart Citation

Drug Loading and Release from Electrospun Biodegradable Nanofibers

Goonoo¹,

Bhaw‐Luximon²,

Jhurry³

2014

j biomed nanotechnol

View full text Add to dashboard Cite

This review explores the potential of electrospun nanofibers for drug delivery applications. In the first section, some of the key challenges in drug delivery as well as the promise of electrospun drug loaded nanofibers are highlighted. Techniques of drug incorporation into nanofibers such as blending, surface modification and co-axial electrospinning are detailed. The major requirements of drug eluting scaffolds such as biocompatibility and biodegradability, efficient drug control and release, and adequate mechanical performance are addressed. Drug release kinetics, biodegradability and mechanical properties can be controlled by careful selection of polymers and electrospinning processing parameters while biocompatibility of electrospun mats may be enhanced through surface modification of the nanofibers. The major applications as well as the routes of administration of the drug-loaded electrospun nanostructures are discussed. Currently available drug eluting nanofibrous mats for applications ranging from cancer therapy to wound dressings as well as their preclinical trials are also reviewed.

show abstract

Section: Fiber Diameter and Porositymentioning

confidence: 99%

“…Paclitaxel-eluting bioresorbable core/shell fiber structures for local cancer treatment were developed by Kraitzer et al 140 These structures were composed of a polyglyconate core and a porous PDLGA shell loaded with the anti-proliferative agent paclitaxel. Paclitaxel (PXL) release from the porous shell was relatively slow.…”

Section: Applicationsmentioning

confidence: 99%

Drug Loading and Release from Electrospun Biodegradable Nanofibers

Goonoo¹,

Bhaw‐Luximon²,

Jhurry³

2014

j biomed nanotechnol

View full text Add to dashboard Cite

show abstract

“…In recent years, various groups of researchers have investigated the development of novel formulations for PTX, including liposomes, [10][11][12][13][14][15] emulsions, [16][17][18][19] cyclodextrins, [20][21][22] microspheres, 23,24 nanoparticles, [25][26][27][28][29][30][31] and implants. [32][33][34][35] In addition, injectable thermoreversible hydrogels are also being developed with reasonable success for PTX delivery. [36][37][38][39] The unique advantages of this kind of drug delivery system, which include the provision of targeted cytotoxicity, and controlled release of a drug without systemic toxicities, have made it more and more attractive as a system with great potential for treating cancer.…”

Section: Introductionmentioning

confidence: 99%

Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies

Nie¹,

Hsiao²,

Pan³

et al. 2011

IJN

120

View full text Add to dashboard Cite

Purpose To develop an in situ gel system comprising liposome-containing paclitaxel (PTX) dispersed within the thermoreversible gel (Pluronic ® F127 gel) for controlled release and improved antitumor drug efficiency. Methods The dialysis membrane and membrane-less diffusion method were used to investigate the in vitro drug release behavior. Differential scanning calorimetry (DSC) thermal analysis was used to investigate the “micellization” and “sol/gel transition” process of in situ gel systems. In vitro cytotoxicity and drug uptake in KB cancer cells were determined by MTT, intercellular drug concentration, and fluorescence intensity assay. Results The in vitro release experiment performed with a dialysis membrane model showed that the liposomal gel exhibited the longest drug-release period compared with liposome, general gel, and commercial formulation Taxol ® . This effect is presumably due to the increased viscosity of liposomal gel, which has the effect of creating a drug reservoir. Both drug and gel release from the in situ gel system operated under zero-order kinetics and showed a correlation of release of PTX with gel, indicating a predominating release mechanism of the erosion type. Dispersing liposomes into the gel replaced larger gel itself for achieving the same gel dissolution rate. Both the critical micelle temperature and the sol/gel temperature, detected by DSC thermal analysis, were shifted to lower temperatures by adding liposomes. The extent of the shifts depended on the amount of embedded liposomes. MTT assay and drug uptake studies showed that the treatment with PTX-loaded liposomal 18% Pluronic F127 yielded cytotoxicities, intercellular fluorescence intensity, and drug concentration in KB cells much higher than that of conventional liposome, while blank liposomal 18% Pluronic F127 gel was far less than the Cremophor EL ® vehicle and empty liposomes. Conclusions A thermosensitive hydrogel with embedded liposome is a promising carrier for hydrophobic anticancer agents, to be used in parenteral formulations for treating local cancers.

show abstract

“…This would include multi-scale modeling of drug pharmacokinetics and metabolism [44], as well as tissue partitioning and drug binding [45] in a heterogeneous tissue structure with more realistic diseased vessel topography. In those cases, the time-dependence of drug release [46] and the process of drug binding to tissue proteins will more accurately determine the ultimate drug uptake [47, 48]. Assuming a more dynamic environment of biological host species, vascular response both to the intravascular implant and depleted drug in terms of intimal hyperplasia and thrombosis should also be included in future numerical models to better assess the efficacy of new generations of drug-eluting implants [49] in more sophisticated clinical routines such as overlap [50, 51].…”

Section: Discussionmentioning

confidence: 99%

Drug deposition in coronary arteries with overlapping drug-eluting stents

Rikhtegar

Edelman

Olgaç

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

Drug-eluting stents are accepted as mainstream endovascular therapy, yet concerns for their safety may be under-appreciated. While failure from restenosis has dropped to below 5%, the risk of stent thrombosis and associated mortality remain relatively high. Further optimization of drug release is required to minimize thrombosis risk while maintaining therapeutic dose. The complex three-dimensional geometry of deployed stents together with the combination of diffusive and advective drug transport render an intuitive understanding of the situation exceedingly difficult. In situations such as this, computational modeling has proven essential, helping define the limits of efficacy, determine the mode and mechanism of drug release, and identify alternatives to avoid toxicity. A particularly challenging conformation is encountered in coronary arteries with overlapping stents. To study hemodynamics and drug deposition in such vessels we combined high-resolution, multi-scale ex vivo computed tomography with a flow and mass transfer computational model. This approach ensures high geometric fidelity and precise, simultaneous calculation of blood flow velocity, shear stress and drug distribution. Our calculations show that drug uptake by the arterial tissue is dependent both on the patterns of flow disruption near the wall, as well as on the relative positioning of drug-eluting struts. Overlapping stent struts lead to localized peaks of drug concentration that may increase the risk of thrombosis. Such peaks could be avoided by anisotropic stent structure or asymmetric drug release designed to yield homogeneous drug distribution along the coronary artery and, at the least, suggest that these issues need to remain in the forefront of consideration in clinical practice.

show abstract

Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structures

Cited by 29 publications

References 27 publications

Drug Loading and Release from Electrospun Biodegradable Nanofibers

Drug Loading and Release from Electrospun Biodegradable Nanofibers

Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies

Drug deposition in coronary arteries with overlapping drug-eluting stents

Contact Info

Product

Resources

About

Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structures

Cited by 29 publications

References 27 publications

Drug Loading and Release from Electrospun Biodegradable Nanofibers

Drug Loading and Release from Electrospun Biodegradable Nanofibers

Thermoreversible Pluronic&reg; F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies

Drug deposition in coronary arteries with overlapping drug-eluting stents

Contact Info

Product

Resources

About

Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies